Following the success of various clinical studies, the radiopharmaceuticals [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL for positron emission tomography (PET) and [177Lu]Lu-PSMA-617 for radionuclide treatment have recently been approved by the FDA and EMA for PCa patients (7–9). The gene discussed is FOLH1; the disease is posterior cortical atrophy.